Cure My Disease

Don't miss your cure!

 Log in / Sign up

Supercharged immune cells take on tough T-Cell cancers

NCT ID NCT07137481

Not yet recruiting Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose tumors express a protein called CD5. The main goals are to check safety and see how long patients stay cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
engineered natural killer (NK) cells (CD5 CAR IL-15 NK cells) plus chemotherapy drugs (fludarabine, cyclophosphamide, rituximab)
What this could lead to
If successful, this could offer a new consolidation therapy to keep aggressive T-cell cancers in remission longer after initial treatment.
What could go wrong
This is a Phase 2 trial with only 70 participants, so results are preliminary. The therapy involves strong chemotherapy and engineered cells, which may cause serious side effects like infections or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK-NEGATIVE, DUSP22-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ALK-negative anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm hepatosplenic T-cell lymphoma peripheral T-cell lymphoma, not otherwise specified T lymphoblastic leukemia/lymphoma T-cell non-Hodgkin lymphoma T-cell prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.